ArticleParkinson's disease2011
Drosophila models of Parkinson's disease: discovering relevant pathways and novel therapeutic strategies.
Article in Parkinson's disease, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 37 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
37 citing papers in PubMed, 100 citations in OpenAlex.
- Symptomatic Rescue or Disease Modification? A Critical Review of Levodopa and Phytochemical Interventions in Caenorhabditis elegans Models of Parkinson's Disease.Molecular neurobiology · 2026Review
- Species-dependent activities of the PINK1-parkin axis.Translational neurodegeneration · 2026Review
- D-ribose-L-cysteine and lauric acid co-treatment confers multi-pathway neuroprotection in an alpha-synuclein transgenic Drosophila model of Parkinson's disease.Metabolic brain disease · 2026Article
- Acteoside exerts neuroprotective effects by preventing α-synuclein aggregation and oxidative stress in models of Parkinson's disease.Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics · 2026Article
- In Vitro Antioxidant Activity and In Vivo Neuroprotective Effect ofAntioxidants (Basel, Switzerland) · 2025Article
- A rationally designed microbial consortium modulates neurodegeneration in a Drosophila melanogaster model of Parkinson's disease.NPJ biofilms and microbiomes · 2025Article
- Clearance Pathways for α-Synuclein in Parkinson's Disease.Journal of neurochemistry · 2025Review
- Neurobiology of psilocybin: a comprehensive overview and comparative analysis of experimental models.Frontiers in systems neuroscience · 2025Review
- Chemical Characterization and Beneficial Effects of Walnut Oil on aMolecules (Basel, Switzerland) · 2024Article
- Two Old Wild-Type Strains ofInsects · 2024Article
- Primary cilia in Parkinson's disease: summative roles in signaling pathways, genes, defective mitochondrial function, and substantia nigra dopaminergic neurons.Frontiers in aging neuroscience · 2024Review
- A new metabolic model ofLife science alliance · 2023Article
- Predicting structural features of selected flavonoids responsible for neuroprotection in a Drosophila model of Parkinson's disease.Neurotoxicology · 2023Article
- Analysis of α-syn andFrontiers in cellular neuroscience · 2023Article
- Sexual dysfunction precedes motor defects, dopaminergic neuronal degeneration, and impaired dopamine metabolism: Insights fromFrontiers in neuroscience · 2023Article
- Exploring the link between Parkinson's disease and type 2 diabetes mellitus in Drosophila.FASEB journal : official publication of the Federation of American Societies for Experimental Biology · 2022Article
- A High-Throughput Chemical Screen in DJ-1β Mutant Flies Identifies Zaprinast as a Potential Parkinson's Disease Treatment.Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics · 2021Article
- Comprehensive Perspectives on Experimental Models for Parkinson's Disease.Aging and disease · 2021Review
- Dietary Macronutrient Management to Treat Mitochondrial Dysfunction in Parkinson's Disease.International journal of molecular sciences · 2019Review
- Effect of Majun Baladur on life span, climbing ability, oxidative stress and dopaminergic neurons in the transgenicHeliyon · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Parkinson's disease (PD) is the second most common neurodegenerative disorder and is mainly characterized by the selective and progressive loss of dopaminergic neurons, accompanied by locomotor defects. Although most PD cases are sporadic, several genes are associated with rare familial forms of the disease. Analyses of their function have provided important insights into the disease process, demonstrating that three types of cellular defects are mainly involved in the formation and/or progression of PD: abnormal protein aggregation, oxidative damage, and mitochondrial dysfunction. These studies have been mainly performed in PD models created in mice, fruit flies, and worms. Among them, Drosophila has emerged as a very valuable model organism in the study of either toxin-induced or genetically linked PD. Indeed, many of the existing fly PD models exhibit key features of the disease and have been instrumental to discover pathways relevant for PD pathogenesis, which could facilitate the development of therapeutic strategies.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.